Related Experiment Videos
Effects of synthetic form of tracheal antimicrobial peptide on respiratory pathogens
1Depariment of Internal Medicine Pulmonary Division, Southern Illinois University, Springfield 62702, USA.
Abstract:
We have synthesized a C-terminal portion of tracheal antimicrobial peptide (TAP) with 38 amino acids and tested it for efficacy on various clinical isolates of Pseudomonas aeruginosa strains from patients with cystic fibrosis and also on Aspergillus fumigatus. Our results indicate that the synthetic TAP has both potent bactericidal and fungicidal activities and that a combination of TAP and amphotericin B showed strong additive effects of growth inhibition on A fumigatus. These results suggest that TAP is potentially an effective therapy for Aspergillus and multi-drug-resistant Pseudomonas, pathogens that are often a serious threat to patients with cystic fibrosis.
Insights
Synthetic tracheal antimicrobial peptide (TAP) shows potent bactericidal and fungicidal activity against Pseudomonas aeruginosa and Aspergillus fumigatus. This peptide offers potential new therapies for cystic fibrosis patients battling these serious infections.
Area of Science:
- Antimicrobial Peptides
- Infectious Diseases
- Respiratory Medicine
Background:
- Cystic fibrosis (CF) patients are susceptible to serious infections.
- Pseudomonas aeruginosa and Aspergillus fumigatus are common CF pathogens.
- Drug-resistant strains pose a significant therapeutic challenge.
Purpose of the Study:
- To synthesize and evaluate the antimicrobial efficacy of a C-terminal portion of tracheal antimicrobial peptide (TAP).
- To assess TAP's activity against clinical isolates of Pseudomonas aeruginosa and Aspergillus fumigatus from CF patients.
- To investigate the combined effect of TAP and amphotericin B on Aspergillus fumigatus.
Main Methods:
- Synthesis of a 38-amino acid C-terminal fragment of TAP.
- Testing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa.
- Evaluating antifungal activity against Aspergillus fumigatus.
- Assessing synergistic effects with amphotericin B.
Main Results:
- Synthetic TAP demonstrated potent bactericidal activity against Pseudomonas aeruginosa.
- Synthetic TAP exhibited significant fungicidal activity against Aspergillus fumigatus.
- A combination of TAP and amphotericin B showed additive growth inhibition of Aspergillus fumigatus.
Conclusions:
- Tracheal antimicrobial peptide (TAP) is a promising candidate for treating infections in cystic fibrosis patients.
- TAP shows potential efficacy against multi-drug-resistant Pseudomonas aeruginosa and Aspergillus fumigatus.
- Combination therapy with TAP may enhance treatment outcomes for fungal co-infections.